Filing Details

Accession Number:
0001209191-15-075198
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-13 13:29:21
Reporting Period:
2015-10-13
Filing Date:
2015-10-13
Accepted Time:
2015-10-13 13:29:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1557746 Aclaris Therapeutics Inc. ACRS Pharmaceutical Preparations (2834) 460571712
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1509160 Vivo Ventures Fund Vii, L.p. C/O Vivo Capital
575 High Street, Suite 201
Palo Alto CA 94301
No No Yes No
1538309 Vivo Ventures Vii Affiliates Fund, L.p. C/O Vivo Capital
575 High Street, Suite 201
Palo Alto CA 94301
No No Yes No
1565020 Vivo Ventures Vii, Llc C/O Vivo Capital
575 High Street, Suite 201
Palo Alto CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-13 3,360,408 $0.00 3,657,147 No 4 C Indirect By Vivo Ventures Fund VII, L.P.
Common Stock Acquisiton 2015-10-13 444,850 $11.00 4,101,997 No 4 P Indirect By Vivo Ventures Fund VII, L.P.
Common Stock Acquisiton 2015-10-13 73,238 $0.00 79,705 No 4 C Indirect By Vivo Ventures VII Affiliates Fund, L.P.
Common Stock Acquisiton 2015-10-13 9,695 $11.00 89,400 No 4 P Indirect By Vivo Ventures VII Affiliates Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Vivo Ventures Fund VII, L.P.
No 4 P Indirect By Vivo Ventures Fund VII, L.P.
No 4 C Indirect By Vivo Ventures VII Affiliates Fund, L.P.
No 4 P Indirect By Vivo Ventures VII Affiliates Fund, L.P.
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2015-10-13 8,467,943 $0.00 2,454,476 $0.00
Common Stock Series A Preferred Stock Disposition 2015-10-13 184,557 $0.00 53,494 $0.00
Common Stock Series B Preferred Stock Disposition 2015-10-13 1,779,400 $0.00 515,768 $0.00
Common Stock Series B Preferred Stock Disposition 2015-10-13 38,782 $0.00 11,241 $0.00
Common Stock Series C Preferred Stock Disposition 2015-10-13 1,346,068 $0.00 390,164 $0.00
Common Stock Series C Preferred Stock Disposition 2015-10-13 29,337 $0.00 8,503 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
  2. Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
  3. Vivo Ventures VII, LLC ("VV LLC") is the general partner of Vivo Ventures Fund VII, L.P. ("VVF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
  4. VV LLC is the general partner of Vivo Ventures VII Affiliates Fund, L.P. ("VVAF"), the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, each of Albert Cha, a director of the issuer, Frank Kung and Edgar Engleman is a managing member of VV LLC and may be deemed to share voting and dispositive power over the securities held by VVAF. Each of such individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.